Literature DB >> 20020238

Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.

Ei Tae Kim1, Lee Hoo Kim1, Jung Il Lee2, Hee Seung Chin3,4.   

Abstract

BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.
METHODS: Thirty-two patients with chronic hepatitis C were examined prospectively for changes in fundus findings while they were being treated with pegylated interferon and ribavirin. Patients were followed with sequential ocular examinations for a maximum of 36 weeks.
RESULTS: Eleven of the 32 patients (34.4%) developed retinopathy. Cotton-wool spots were found in six patients, retinal hemorrhages in four, and branch retinal vein occlusion in one (one eye). Hypertension was found to be the most significant risk factor for developing retinopathy.
CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon. The valid risk factor for developing retinopathy is hypertension. The high rate of retinopathy in patients with hypertension suggests that patients should be carefully monitored.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20020238     DOI: 10.1007/s10384-009-0738-8

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  14 in total

1.  Ocular complications with high-dose interferon alpha in chronic active hepatitis.

Authors:  S Kadayifcilar; S Boyacioglu; H Kart; M Gursoy; P Aydin
Journal:  Eye (Lond)       Date:  1999-04       Impact factor: 3.775

Review 2.  Side effects of therapy of hepatitis C and their management.

Authors:  Michael W Fried
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

4.  Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.

Authors:  K Jain; W C Lam; S Waheeb; Q Thai; J Heathcote
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

5.  Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C.

Authors:  H Saito; H Ebinuma; H Nagata; Y Inagaki; Y Saito; K Wakabayashi; T Takagi; M Nakamura; H Katsura; Y Oguchi; H Ishii
Journal:  Liver       Date:  2001-06

Review 6.  Interferon alfa-associated retinopathy.

Authors:  R B Chambers; A Downie; B Foote; F H Davidorf
Journal:  J Am Osteopath Assoc       Date:  1997-01

7.  Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa.

Authors:  S Hayasaka; M Fujii; Y Yamamoto; S Noda; H Kurome; M Sasaki
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

8.  Interferon-associated retinopathy.

Authors:  D R Guyer; J Tiedeman; L A Yannuzzi; J S Slakter; D Parke; J Kelley; R A Tang; M Marmor; G Abrams; J W Miller
Journal:  Arch Ophthalmol       Date:  1993-03

9.  Is screening for interferon retinopathy in hepatitis C justified?

Authors:  F M Cuthbertson; M Davies; M McKibbin
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

10.  Pegylated interferon-associated retinopathy in chronic hepatitis C patients.

Authors:  Hiroko Ogata; Hiromasa Suzuki; Kimiya Shimizu; Hitoshi Ishikawa; Namiki Izumi; Masayuki Kurosaki
Journal:  Jpn J Ophthalmol       Date:  2006 May-Jun       Impact factor: 2.211

View more
  9 in total

1.  [Acute loss of vision during therapy of chronic hepatitis C].

Authors:  J P Salgado; R Khoramnia; M M Maier; C P Lohmann; C Winkler von Mohrenfels
Journal:  Ophthalmologe       Date:  2011-06       Impact factor: 1.059

Review 2.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 3.  A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan.

Authors:  Heather Bennett; Nathalie Waser; Karissa Johnston; Jia-Horng Kao; Young-Suk Lim; Zhong-Ping Duan; Youn-Jae Lee; Lai Wei; Chien-Jen Chen; William Sievert; Yong Yuan; Hong Li
Journal:  Hepatol Int       Date:  2015-06-13       Impact factor: 6.047

Review 4.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

Review 5.  Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.

Authors:  Ji-Hua Xue; Hai-Hong Zhu; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 6.  Thrombosis Associated with Viral Hepatitis.

Authors:  Luca Galli; Victor E A Gerdes; Luigina Guasti; Alessandro Squizzato
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

7.  Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy.

Authors:  Muhammad Kashif; Muhammad Khurram Saleem; Imran Khan Farooka; Amina Husnain; Arif Mahmood Siddiqui
Journal:  Pak J Med Sci       Date:  2015 Jan-Feb       Impact factor: 1.088

8.  Systemic abnormalities associated with retinal vein occlusion in young patients.

Authors:  Suthasinee Sinawat; Chavisa Bunyavee; Tanapat Ratanapakorn; Supat Sinawat; Wipada Laovirojjanakul; Yosanan Yospaiboon
Journal:  Clin Ophthalmol       Date:  2017-02-23

9.  Structural evaluation of the peritubular sheath of rat's testes after administration of ribavirin: A possible impact on the testicular function.

Authors:  Shaima M Almasry; Zeinab A Hassan; Wael M Elsaed; Yasser M Elbastawisy
Journal:  Int J Immunopathol Pharmacol       Date:  2017-08-11       Impact factor: 3.219

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.